REG - Immupharma PLC - Incanthera - Comm'l Skincare Deal/£1M Fundraise

ImmuPharmaAnnouncement

18/12/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231218:nRSR0696Xa&default-theme=true

RNS Number : 0696X  Immupharma PLC  18 December 2023

18 December 2023

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Incanthera Secures Commercial Skincare Deal & £1M Fundraise

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, is delighted to highlight the announcement issued this morning by
Incanthera plc ("Incanthera"), the dermatology and oncology specialist, in
which ImmuPharma currently holds a 12.7% shareholding.

 

Within the announcement, Incanthera announces a significant commercial
skincare deal with Marionnaud (part of the A.S. Watson Group) initially across
Europe and further roll outs in Asia. It confirmed that this deal is expected
to generate significant revenues and profitability for Incanthera, in 2024 and
beyond.

 

In conjunction Incanthera announces that it has concluded a successful
fundraise of £1,000,000, with new and existing institutional investors which
was oversubscribed, and is priced at £0.07, a premium of 11.1% to the
mid-market price at the close of trading on Friday 15 December 2023.

 

Incanthera trades on Aquis Stock Exchange ("AQSE") under the ticker
(AQSE:INC). For full details of the announcement, please visit Incanthera's
website: https://incanthera.com/investors/regulatory-news/
(https://incanthera.com/investors/regulatory-news/) .

 

Commenting on Incanthera's announcement, Dr Tim Franklin, COO of ImmuPharma
said: "As a major shareholder in Incanthera, we are delighted with this
significant milestone, which highlights the enormous opportunities within
Incanthera's revolutionary skincare range."

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Dr Tim Franklin, COO

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650/51

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(https://www.immupharma.co.uk/)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in
dermatology and oncology. It seeks to identify and develop innovative
solutions to current clinical, commercially relevant unmet needs, utilising
new technology from leading specialists and academic institutions as well as
its in-house development team.

 

Incanthera originated from the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford.  Incanthera's strategy is to develop each
candidate in its portfolio from initial acquisition or discovery to securing
its future through commercially valuable partnerships at the earliest
opportunity in its development pathway.

 

For more information on Incanthera please visit: www.incanthera.com
(http://www.incanthera.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBORRORUUAUA